Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function-a prespecified substudy from REDUCE-AMI.
Katarina MarsSophia Monica HumphriesPhilip LeissnerMartin JonssonPatric KarlströmJörg LauermannJoakim AlfredssonThomas KellerthAnnica Ravn FischerDavid ErlingeBertil LindahlTroels YndigegnTomas JernbergClaes HeldErik M G OlssonRobin HofmannPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
Among patients after AMI with preserved left ventricular ejection fraction, self-reported quality of life and well-being was not significantly different in individuals randomized to routine long-term beta-blocker therapy as compared to individuals with no beta-blocker use. These results appear consistent regardless of adherence to randomized treatment and across subgroups which emphasizes the need for a careful individual risk-benefit evaluation prior to initiation of beta-blocker treatment.
Keyphrases
- left ventricular
- ejection fraction
- acute myocardial infarction
- aortic stenosis
- heart failure
- angiotensin converting enzyme
- open label
- double blind
- phase iii
- clinical trial
- phase ii
- hypertrophic cardiomyopathy
- stem cells
- combination therapy
- metabolic syndrome
- randomized controlled trial
- acute coronary syndrome
- atrial fibrillation
- coronary artery disease
- angiotensin ii
- smoking cessation
- glycemic control